Zimmer Biomet deal fallout: new leader in hips and knees, S and N to lose out?
This article was originally published in Clinica
Executive Summary
Zimmer’s $13.35bn purchase of Biomet, agreed last week, looks set to create a new market leader in large joint reconstruction, according to Goldman Sachs analyst David Roman. He estimates that the new combined company has 39% of the sector, which comprises hip and knee implants, followed by Johnson & Johnson with 23%, Stryker with 21%, then Smith & Nephew with 12%.